Survivin is expressed in most cancers but is undetectable in differentiated adult cells, and plays an important role both in the suppression of apoptosis and mitotic spindle checkpoint; thus it has attracted great interest as a potential drug target. In this study, we investigated the antigene and antiproliferative effects of triplex-forming oligodeoxynucleotides (TFO) targeting survivin in human lung carcinoma A549 cells. Survivin-specific TFOs form stable triplexes under physiological conditions as tested by electrophoretic mobility shift assays. Treatment of A549 cells with survivin-specific but not control TFOs at a concentration of 400 nM in the presence of uptake-enhancing liposome significantly reduced survivin protein level, inhibited cell proliferation, and induced cell apoptosis as demonstrated by immunoblot, cell number counting, and Annexin V-staining. Moreover, we found that the triplex-forming potential of TFOs measured in vitro does not necessarily correlate with the ability of TFOs to affect expression of a targeted gene in vivo. Our results indicate that targeting survivin is a promising alternative strategy for the development of novel anticancer therapeutics.
I
nhibitors of apoptosis proteins (IAPs) are a family of evolutionarily conserved apoptosis suppressors [1] [2] [3] and potently inhibit activated caspases to arrest apoptosis induced by either intrinsic (mitochondria) or extrinsic (death receptor) pathways. [4] [5] [6] Overexpression of XIAP, c-IAP1, c-IAP2, NAIP, or survivin has been shown to suppress apoptosis induced by a variety of stimuli including TNF, Fas, menadione, staurosporin, etoposide (VP16), Taxol, and growth factor withdrawal. [7] [8] [9] [10] Among them, survivin is overexpressed in developing fetus and many common cancers, but largely absent from normal adult cells, thus making survivin an exciting new tumor marker. 9, 11 It has been shown by genome-wide transcription profiling that survivin is one of the most tumor-specific genes thus far identifiable. 12 The survivin gene is cell cycle regulated and specifically active in the late G2/M phase. 10 Moreover, survivin protein physically associates with mitotic chromosomes and mitotic spindle apparatus and plays a pivotal role in ensuring accurate chromosome segregation during anaphase and in the final execution of cytokinesis. 10 Suppression of survivin by antisense or interference with survivin function by dominant-negative mutants affecting the baculovirus IAP repeat (BIR) result in dysregulation of mitotic progression and spontaneous apoptosis without any other proapoptotic stimulus. [13] [14] [15] [16] Moreover, this response is unique to survivin and not observed with other apoptosis inhibitors potentially contributing to neoplasia. For example, targeting bcl-2 with antisense oligonucleotides increases sensitivity to apoptosis but is insufficient in itself to induce cell death. 17 These observations suggest that targeting survivin is a promising strategy for anticancer drug development.
Apoptosis-based therapeutics are now being tested in human clinical trials and have shown efficiency in preclinical animal models. Antisense oligonucleotides (Bcl-2, FLIP, and survivin), recombinant biologicals (TRAIL), and classical organic pharmaceuticals (caspases) are examples of three of the most advanced and promising opportunities, which will set the stage for many future therapeutics, and represent different therapeutic modalities. 18 Oligonucleotides have been developed to bind site-selectively to DNA (antigene or TFOs), to RNA (antisense and ribozyme), and to protein (aptamers). 19 Triplex-forming oligonucleotides (TFOs) have attracted a great deal of attention because of their ability to specifically bind to double-strand DNA and their potential use in gene therapy. Purine and pyrimidine oligonucleotides targeted to homopurine/homopyrimidine-rich sequences form pur*pur Á pyr and pyr*pur Á pyr intermolecular triple helices. The oligonucleotide third strand occupies the major groove of the duplex, forming Hoogsteen or reverse Hoogsteen hydrogen bonds with the purine bases of the duplex DNA. Both pur*pur Á pyr and mixed pur/pyr*pur Á pyr triplexes can be formed at physiological pH with predominantly G*G Á C triplets along with A*A Á T and T*A Á T triplets. 20, 21 Many groups have reported TFO-mediated activivties in cell culture experiments including the modulation of gene expression and the induction of genomic modifications at specific sites. [20] [21] [22] [23] [24] [25] TFO-associated inhibition of transcription can be achieved by interfering with transcription initiation through competition with transcription factors at the promoter or interfering with transcription elongation through RNA synthesis arrest at triplex structure. Besides inhibition of transcription, the specific and stable structures formed by TFO with genomic sites might induce cell cycle arrest. 26 In this study, we utilized this antigene strategy to target survivin in human lung carcinoma A549 cells and our results suggest that the triplex technique is a promising tool for anticancer therapeutics.
Materials and methods

Design of oligonucleotides
The structure of survivin gene (GenBank U75285) and sequences of target sites and TFOs are shown in Figure 1 . The control oligonucleotide SCR24-PS (5 0 GAGAGAGGAAGGGTGGGATAGAGG3 0 ) has the same nucleotide length but with five mismatched nucleotides in different positions compared to sur4-GAT24-PS. All oligonucleotides were either partially phosphorothioated (phosphorothioated at 5 0 and 3 0 ends, PO) or completely phosphorothioated on the whole backbone of the oligonucleotides (PS). For cellular uptake and intracellular stability study, oligonucleotides were additionally conjugated with fluorochrome (FITC) at their 5 0 ends. TFOs were designed to bind to target duplex DNA in an antiparallel motif relative to the purine strand. Specific TFOs and control oligonucleotides were commercially obtained and purified by HPLC (Thermo Hybaid, Ulm, Germany).
We have found four binding sites for TFOs in the survivin gene. In intron II, there is a 24 nt polypurine/ polypyrimidine-rich sequence at 3013-3036 with two C Á G interversions. The guanine content of this polypurine/ polypyrimidine-rich sequence is 71%, and it has three GGGG and two GGG structures. Therefore, TFOs can bind to this target with a very high affinity despite two C Á G interversions within the target. Corresponding purine motif TFOs were designed to bind to the purine strand of target DNA in an antiparallel way. For these two C Á G interversions, we used thymidine to recognize C Á G to form T*C Á G triplets. In intron II, there is another 23 nt polypurine/polypyrimidine-rich sequence at 3077-3099 with two C.G interversions. The guanine content of this polypurine/polypyrimidine-rich sequence is 61%, and it has two GGGG and one GGG structures. TFOs were designed according to the above 24 nt target. If TFOs can specifically bind to these sequences inside intron II, transcription elongation will be arrested, and expression of survivin will be inhibited. Downstream the coding region of survivin gene, we found two TFO binding sequences located at 12263-12286 and 12329-12350. The first is a 24 nt homopurine sequence with eight consecutive GA repeats along the sequence. Compared to the other target sites, the guanine content is low with 37.5%, but with its unique sequence, a triplex might also form. The second is a 22 nt polypurine/polypyrimidinerich sequence with one T Á A interversion, the guanine content of this sequence is 54.5%, and cytosine was used to recognize this T Á A interversion (Fig 1) .
Electrophoretic mobility shift assay
Double-stranded oligonucleotides were prepared and electrophoretic mobility shift assay (EMSA) was carried out as described. 27 Cell line and culture condition
The human lung carcinoma cell line A549 was obtained from DSMZ (German Institute for Micro-organism and Cell Culture, Heidelberg, Germany). Cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS). Cells were cultured at 371C with 85% humidity and 5% CO 2 .
Cellular uptake and intracellular stability
To investigate the cellular uptake and intracellular stability of the TFOs targeting survivin in A549 cells, oligonucleotides were additionally conjugated with fluorochrome (FITC) at their 5 0 ends. FITC-conjugated TFOs were added to cells at different concentrations directly or transfected under the help of liposome according to the manufacturer's instruction (Roche Molecular Biochemicals, Mannheim, Germany), and then the cells were analyzed by fluorescence microscopy (NIKON TE300, Japan) and FACS (Becton Dickinson Immunocytometry Systems, San Jose, CA).
Treatment of A549 cells with TFOs
To investigate the inhibitory effects of TFOs on endogenous survivin gene, 0.2 Â 10 6 A549 cells were plated in each well of six-well plates the day before transfection. A volume of 6 mg of the polycationic liposome DOSPER was diluted in 500 ml DMEM medium without FCS. At the same time, 4 ml of 100 pmol/ml oligonucleotide was diluted in 500 ml DMEM medium without FCS. Then the above two solutions were mixed gently and incubated at room temperature for 30 minutes to form a DNA/liposome complex. Immediately prior to transfection, cells were washed twice with Ca 2+ -and Mg 2+ -free sterile PBS. Following 30 minutes of incubation, the 1 ml liposome/DNA complex was added to each well. The plates were incubated for 5 hours at 371C, then 1 ml of DMEM containing 20% FCS was added. After 24 hours, the cells were transfected again. At 48 hours after the first transfection, cells were harvested for Western blot, cell number counting, and FACS. The remaining samples were transfected again. After 72 and 96 hours, cells were harvested for Western blot, cell number 
Western blot of survivin
Total proteins (50 mg per lane) were resolved on a 10% SDS-polyacrylamide gel at 180 V for 60 minutes and transferred onto a nylon membrane using semidry transferring at 100 mA for 60 minutes. Thereafter, the membrane was blocked with 1% BSA in TBS for 30 minutes. Actin proteins were detected using a 1:5000 dilution of a monoclonal antiactin antibody (Sigma, Saint Louis, MO). HRP-conjugated anti-mouse IgG secondary antibody (Jackson ImmunoResearch Laboratories, Inc., Hamburg, Germany) was used at 1:10,000 dilution and was visualized using the enhanced chemiluminescence (ECL) system (PIERCE, Rockford, IL). After washing once with TBS (0.05 % Tween 20), the membrane was incubated with 2 mg/ml rabbit antisurvivin (N-terminal) polyclonal antibody (Alexis Deutschland GmbH, Gruenberg, Germany) at 41C overnight. After washing with TBS (0.05% Tween 20), the membrane was incubated with goat anti-rabbit IgG (whole molecule) peroxidase conjugate (Sigma Aldrich, Steinheim, Germany) in a dilution of 1:5000 for 1 hour at room temperature. After washing with TBS (0.05% Tween 20), the membrane was detected with chemiluminescence system.
Cell proliferation assay
At different time points after oligonucleotide treatment, cell number was determined with a hemocytometer after detaching the cells with a solution of 1 mg/ml trypsin and 1 mM EDTA. All experiments were repeated three times and data were expressed as mean7SD.
Apoptosis staining
At different time points after transfection, A549 cells were trypsinized, washed once with PBS, then resuspended in 200 ml 1 Â binding buffer according to the manufacturer's instruction (Clontech, Palo Alto, CA). A volume of 5 ml of EGFP-conjugated Annexin V (Clontech, Palo Alto, CA) was added to each sample, and incubated with cells at room temperature for 10 minutes in the dark, then cells were washed once with PBS and resuspended in 500 ml 1 Â binding buffer and analyzed by FACS.
Results
Triplex formation of TFOs targeting survivin
EMSA demonstrated triplex formation of sur4-GAT24-PO and sur4-GAT24-PS with 32 bp DNA target at high binding affinity. sur4-GAT24-PO can convert half of the target (0.1 mM) to triplex at a concentration of 0.2 mM. The binding affinity of sur4-GAT24-PS is about 10-fold lower than that of sur4-GAT24-PO. The binding affinity of sur5-GAT23-PO and sur5-GAT23-PS is similar to that of sur4-GAT24-PO and sur4-GAT24-PS. For sur6-GA24-PS, sur6-GA24-PO, sur7-GAC22-PO, and sur7-GAC22-PS, the binding affinity is much lower than that of sur4-GAT24-PO and sur4-GAT24-PS (Fig 1) .
Cellular uptake and intracellular stability of TFOs targeting survivin in A549 cells
Cellular uptake, intracellular stability and compartmentalization of oligonucleotide, and accessibility of oligonucleotide to chromatin are critical issues for the ultimate successful application of oligonucleotide-mediated gene therapy. In our study, we tried different cationic liposomes and lipids, such as DOSPER and FuGENE 6 (Roche Molecular Biochemicals, Mannheim, Germany), and Effectene (Qiagen, Hilden, Germany). Our results show that, with the help of cationic reagents, the uptake of TFOs targeting survivin is efficient in A549 cells. With the liposome DOSPER, a transfection rate of more than 80% of A549 cells was achieved already 1 hour after transfection of sur6-GA24-PS and sur7-GAC22-PS as determined by FACS. TFOs retain inside cells for up to 72 hours under 400 nM of oligonucleotide and 6 mg/ml of liposome (Fig 2a) . Moreover, fluorescence microscopy shows that these TFOs targeting survivin are efficiently released to the nucleus (Fig 2b and 2c) .
Antiproliferative effects of TFOs
The antiproliferative effects of TFOs targeting survivin were demonstrated by cell number counting. The start cell number of each sample and control was the same (0.2 Â 10 6 ). After treatment with TFOs at a fixed time point, the cell number was counted for each sample and for the control. sur6-GA24-PS, sur6-GA24-PO, sur7-GAC22-PO, and sur7-GAC22-PS significantly showed antiproliferative effects on lung carcinoma cells (Fig 3) .
Antigene effects of TFOs
A549 cells were incubated with TFOs at a concentration of 400 nM for 5 hours in the presence of uptakeenhancing liposomes. Second and third treatments were performed separately 24 and 48 hours after the first incubation. Survivin protein levels were analyzed by Western blot using a rabbit polyclonal antibody specific for human survivin. sur6-GA24-PS and sur7-GAC22-PS, but not controls, apparently decrease the expression of survivin protein levels. However unexpectedly, sur4-GAT24-PS and sur5-GAT23-PS, both of which have very high binding affinity in vitro as shown by EMSA, exert almost no inhibitory effects on survivin expression (Fig 4a) .
Apoptosis induction in A549 cells by TFOs
To test if downregulation of survivin protein level by TFOs can induce spontaneous cell apoptosis, A549 cells were stained with Annexin V-EGFP and analyzed by fluorescence microscopy and FACS after the same treatment as mentioned above. Figure 4b shows that more than 60% of A549 cells were induced to apoptosis by treatment with sur6-GA24-PS 72 hours post-transfec- 
Discussion
Survivin has been widely recognized as an attractive target for anticancer therapy. [9] [10] [11] Survivin mRNA expression is a good marker for unfavorable prognosis in various tumors. 28 Antisense, ribozyme, and dominantnegative construct of survivin have been successfully utilized to inhibit survivin expression or to interfere with its functions, and therefore to induce apoptosis and sensitize cells to chemotherapy. [13] [14] [15] [16] Lung cancer cells express the highest level of survivin found in human tumors. 9 In addition, survivin expression is correlated with shorter survival in patients with nonsmall cell lung cancer. 29 Since there are only two survivin alleles in each cell compared to hundreds to thousands of survivin mRNA molecules, an antigene strategy might be potentially advantageous compared to antisense and ribozyme techniques if TFOs can access and specifically bind to the genomic sites. Therefore, we used triplex technology as an alternative strategy to target survivin in human lung carcinoma A549 cells. Cell number ( x 2500) 48 h after oligodeoxynucleotide treatment Oligodeoxynucleotides Figure 3 Antiproliferative effects of TFOs targeting survivin in A549 cells. A549 cells were incubated with TFOs at a concentration of 400 nM for 5 hours in the presence of uptake-enhancing liposome. At 48 hours after oligonucleotides treatment, cell number was determined with a hemocytometer. All experiments were repeated three times and data were expressed as mean7SD.
Triplex targeting of survivin C Shen et al
Our results demonstrated intracellular inhibition of gene expression and induction of cell apoptosis by phosphorothioate TFOs targeting the 3 0 noncoding region of survivin. Our previous study showed that TFOs targeting bcl-2 at the 3 0 noncoding region can effectively inhibit the transcription elongation in vitro, 27 but no antigene effects were detected when endogenous bcl-2 was treated with these TFOs in cell culture experiments (data not shown). In the present study, we demonstrated that TFOs targeting survivin gene diminish the expression of survivin protein, prohibit cell proliferation, and induce apoptosis of lung carcinoma cells. Our results indicate that the effects of TFOs on endogenous gene expression may depend on the specific chromatin structure of the specifically addressed gene.
Consecutive guanine structures and guanine content may attribute the high binding affinity of TFOs to their targets. Target sur4 has three GGGG and one GGG structure, and target sur5 has two GGGG and one GGG structure, and the binding affinity of TFOs targeting these two targets is high. In contrast, in targets sur6 and sur7, there are no such poly G structures and consequently the binding affinity of these TFOs is rather low. Moreover, the binding affinity is also reflected in the content of guanine in each TFO. The guanine content of sur4, sur5, sur6, and sur7 is 71, 61, 37.5, and 54.5%, respectively. As expected, sur4-GAT24-PO and sur4-GAT24-PS form at very stable triplex with their targets, while the binding affinity of sur6-GA24-PS and sur6-GA24-PO is low, although there is no pyrimidine interversion in their target sequences. We thus hypothesize that the number of poly G structures and guanine content in the target sequence to some extent determine the binding affinity of corresponding purine motif TFOs to the targets. In addition, PSmodified TFOs normally form triple helices at a higher concentration compared to their counterpart PO TFOs. Modification of PO TFOs to PS TFOs can render TFOs a better serum and intracellular stability but reduce the in vitro binding affinity and cause some toxcity to cells, which is the observation of us and other groups. Whether or not this modification also changes the in vivo binding affinity is not yet clearly known.
In this study, we also demonstrated that in vitro binding affinity does not predict the effects in in vivo complicated situations. Although the triplex strategy has been evaluated for many genes and inhibitory effects have Another concern is that G-rich TFOs (say TFOs targeting sur4 and sur5) have the potential to form quadruplex structures as tested by in vitro experiments, 30 even though it is not sure if these structures form inside cells. Moreover, as we know, the principal regulation of gene expression is transcription initiation. Given that a TFO can bind to DNA sequence downstream promoters (such as sur4 and sur5), the TFO may be removed by some unknown mechanisms during transcription elongation. In addition, EMSA was used to show in vitro triplex formation, and in these experiments the concentration of target DNA is 0.1 mM in our EMSA. However in cell culture, the situation is quite different. There are only two alleles of survivin gene inside each cell, and the concentration of target is much lower than 0.1 mM as in vitro EMSA. Therefore, it is uncertain whether or not a TFO forming an in vitro triplex at very high concentration (low binding affinity) could form a stable triplex in vivo and exert antigene effects. Our results may suggest a new challenge for the triplex strategy and propose some new questions regarding the selection of target sequences of TFOs.
In conclusion, our results demonstrate that synthetic oligonucleotides form stable triplexes with the natural sequence of human survivin and downregulate the expression of survivin protein, significantly inhibit proliferation, and induce apoptosis in lung carcinoma cells. These data indicate that survivin-specific TFOs are promising tools to modulate gene expression and for the inhibition of cancer cell survival.
